Who is Susie Wiles? What to know about Trump's chief of staff

Susie Wiles, the White House chief of staff, was diagnosed with early-stage breast cancer, President Trump announced on March 16; she will continue in her role during treatment and is 68. Wiles has served as Trump's chief of staff since January 2025 and will spend virtually full time at the White House during treatment; Trump described her prognosis as excellent and said treatment began immediately. Wiles has a five-decade political career including work for Jack Kemp, Ronald Reagan, John Delaney, Rick Scott and Ron DeSantis, and has worked on Trump's campaigns since 2015.

Analysis

A shortfall in executive-office bandwidth creates a measurable near-term drag on the cadence of politically risky initiatives — think major health‑care pricing moves, abrupt regulatory rewrites, or high-profile trade actions. Historical analogs show that when top-of-office capacity is constrained, the probability of initiating new, market-moving regulatory actions in the following 60–90 days falls materially (I estimate a 30–50% drop), shifting the balance from headline risk to implementation risk.

That rebalancing benefits large incumbents with regulatory moats and predictable cashflows while compressing the risk premium investors typically price into smaller, binary-outcome biotechs and activist-driven policy trades. Mechanically, procurement schedules, FDA liaison bandwidth, and OMB review cycles get deprioritized — this should widen the relative performance gap between mega-cap pharma/insurers (UNH, PFE, MRK) and small-cap biotech baskets (XBI, IBB) over a 1–6 month window.

Market-level response will likely be muted on day one but skew volatility asymmetrically: volatility of policy-sensitive sectors will rise on any incremental staffing or health updates. The most practical market exposures are short-duration hedges on policy-sensitive indices and selectively overweighting low-beta, policy-resilient names; monitor daily communications cadence and fundraising/appointment signaling as catalysts that would flip the trade within weeks rather than quarters.

Key Decisions for Investors

• Long UnitedHealth (UNH) 3–6 month call spread (buy 1.5–2x delta, sell ~30% higher strike): rationale — lower near-term probability of aggressive pricing/regulatory shocks lifts incumbent margin visibility. Risk: premium paid (~<2–3% of notional); Target: 15–30% return if policy tail cools.
• Short XBI via 1–3 month put spread (buy 3–6% OTM put, sell 10–12% OTM put) sized to ~0.5–1% portfolio risk: rationale — small biotech downside from delayed FDA/market-moving policy and M&A slowdowns. Max loss = premium; reward asymmetry >2:1 if XBI re-prices lower on policy drift.
• Buy SPX 1–2 month 4–6% OTM put spread or 1–2 month VIX calls as a tactical tail hedge (allocate 0.5–1% portfolio): rationale — asymmetric spike risk to policy-sensitive markets on subsequent announcements or staffing changes. Expect payoff in scenario-driven 10–25% intraday moves; cost limited to premium.
• Pair trade: long LMT (or NOC) vs short XBI (equal dollar) for 3–6 months: rationale — defense/industrial budgets and legacy contracting are execution‑resilient while small biotech is most exposed to policy execution risk. Target 8–20% relative outperformance; monitor legislative calendars as exit triggers.